查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835638

嗜睡症治療市場（按藥物類別、疾病類型、年齡層和分銷管道分類）—2025-2032 年全球預測

Narcolepsy Treatment Market by Drug Class, Disorder Type, Age Group, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，嗜睡症治療市場規模將成長至 39.9 億美元，複合年成長率為 8.06%。

主要市場統計數據
基準年2024年 21.4億美元
預計2025年 23.1億美元
預測年份：2032年 39.9億美元
複合年成長率（%） 8.06%

重點介紹將發作性睡病定位為臨床需求、監管進步和商業性機會交匯處的策略治療領域

發作性睡病是一種臨床上複雜的神經系統疾病，其特徵是白天過度嗜睡、夜間睡眠障礙，許多患者甚至會出現猝倒。這種症狀組合顯著降低了生活品質和職場效率，並為診斷、長期管理和治療方法創新帶來了獨特的挑戰。藥理學的最新進展以及對Orexin生物學理解的加深，已將發作性睡病從一種以症狀為主的疾病轉變為一種正在積極研究其緩解疾病機制的疾病。

在這樣的臨床背景下，市場參與企業面臨雙重任務：加速將有前景的科學方法轉化為安全有效的治療方法，同時確保患者公平獲得治療機會和永續的商業模式。生態系統正在快速發展，強調真實世界證據的生成、將藥物治療與行為和技術干預相結合的綜合護理途徑，以及反映長期療效的創新定價模式。本引言強調，決策者必須在短期執行與長期投資（包括研究、夥伴關係和製造韌性）之間取得平衡，以滿足患者需求和相關人員的期望。

以新機制、以病人為中心的照護和不斷變化的監管預期為驅動力，改變嗜睡症治療格局

嗜睡症的治療模式正以多種趨同的方式改變。機制創新，尤其是調節Orexin訊號傳導的努力，正在將臨床焦點從症狀治療轉向更精準的干涉措施，這些干預措施可直接作用於核心病理學。這些科學進步與診斷途徑的改進相輔相成，包括臨床醫生認知度的提高、客觀睡眠測試的普及以及支持症狀追蹤和遠端評估的數位工具。因此，被診斷患者的範圍正在不斷擴大，從而能夠更早地識別出適合高級治療方法的候選患者。

同時，付款人政策和法律規範正在不斷調整，以適應新的治療方法和基於價值的合約模式。醫療保健系統越來越重視與功能改善相關的基於結果的報銷，而不僅僅是短期症狀緩解。以患者為中心的護理模式也越來越受到將藥物治療與行為介入和輔助技術相結合的多學科診所的支持。

基於證據的評估：2025 年美國關稅環境將如何影響供應鏈、製造策略以及患者獲得嗜睡症治療的機會

貿易政策調整和關稅重組正在重新審視全球醫藥供應鏈。對於嗜睡症藥物而言，其影響是多方面的。跨國的活性藥物原料藥和關鍵輔料面臨成本波動加劇和潛在的海關延誤，這可能會影響品牌藥和非專利的生產進度。製造商正在透過評估近岸外包選項、多元化供應商基礎以及加快替代來源的資格認證來應對，以減輕中斷的影響。這些營運響應對於維持供應連續性和避免可能對患者照護產生不利影響的庫存短缺至關重要。

除了營運方面的考量之外，與關稅相關的不確定性也影響整個價值鏈的策略規劃。付款人和醫療保健提供者正在為轉嫁更高採購成本的可能性做準備，並探索強調長期合約、製造商回饋以及製造商贊助的患者援助專案的籌資策略。監管機構和海關當局也面臨簡化基本藥物進口流程的壓力，相關人員擴大倡導對關鍵治療類別實施關稅豁免和加快清關途徑。

策略性細分洞察揭示了治療重點、患者群體細微差別以及與嗜睡症領域決策者相關的分佈動態

細緻的細分框架闡明了臨床需求、發展重點和商業管道的交集。依藥物類別，我們研究了抗憂鬱症、Orexin受體促效劑、羥基丁酸鈉和興奮劑，每種藥物都有不同的功效和安全性以及臨床定位，會影響處方模式和後續護理。按疾病類型，1 型發作性睡病和 2 型發作性睡病的不同病理和管理會影響診斷演算法、特定治療的合格以及新藥試驗設計。按年齡層，成人、老年人和兒童人群之間的差異需要量身定做的給藥策略、安全監測通訊協定和支援服務，以反映發展和合併症的差異。按分銷管道，醫院藥房、線上藥房和零售藥房對營運、法規和病患體驗有不同的影響，從依從性支援到報銷工作流程。

整合這些細分視角可產生多種實際意義。治療開發項目應將作用機制假設與主要臨床表現型細分相結合，以最佳化試驗入組和有意義的終點。商業策略應區分特定管道的提案主張。醫院藥局管道通常強調複雜的配藥和住院連續性，線上藥局管道強調可近性和便利性，零售藥局則支援照護現場和持續依從性。病患援助計畫應根據年齡層和疾病亞型量身定做，以解決現實世界中的依從性障礙和合併症管理。最後，基於細分的證據生成，包括亞組分析和特定管道的健康經濟評估，可加強付款人對話，並促進不同醫療環境中的臨床應用。

關鍵區域分析觀點了監管、醫療保健基礎設施和付款人模式的地理差異如何影響發作性睡病治療的取得和商業化。

動態變化對發作性睡病治療的開發、核准和報銷方式有重大影響。在美洲，臨床實踐模式和付款人結構創造了一種環境，如果有強力的證據表明功能改善，創新就會被迅速採用，製造商通常優先考慮大規模註冊和結果研究，以推進報銷對話。在歐洲、中東和非洲，由於監管途徑不同且醫療保健基礎設施水平參差不齊，因此需要製定市場策略，強調彈性價格設定模式、與當地合作夥伴合作進行分銷以及開展能力舉措舉措以提高診斷覆蓋率。在亞太地區，快速的都市化、新興市場的成長以及不同的監管預期，導致需要採取集中的國家特定採購和區域上市方法相結合的方式，優先考慮擴充性的製造和適應文化的患者支持計劃。

在這些全部區域，相關人員必須協調全球開發計畫和區域准入策略。協調臨床試驗終點與特定區域監管要求，並投資於跨區域真實世界數據收集，將加速報銷和推廣。此外，區域製造地與本地經銷商之間的策略合作夥伴關係可以縮短重要療法的前置作業時間，同時降低關稅和海關相關風險。

關鍵的公司層面洞察揭示了嗜睡症生態系統中創新者、學名藥製造商和服務供應商的戰略態勢、能力差距和夥伴關係機會

企業正透過清晰的策略選擇脫穎而出。擁有專利藥物的創新者通常強調整合證據項目，將對照試驗與現實世界的安全性和健康結果研究相結合，以證明其高階定位的合理性。學名藥生物技術公司專注於創新機制和利基適應症，並尋求夥伴關係和許可協議，以加速開發和獲取藥物。學名藥公司和成熟製藥公司專注於規模化、經濟高效的生產和可靠的分銷網路，以滿足對成熟療法的需求。服務供應商和契約製造製造商將自己定位為韌性賦能者，提供供應鏈冗餘、加速的監管提交支援和品質保證服務，以降低上市時間風險。

在開發初期，許多研發機構若能深入了解付款人參與度並建立健康經濟模型，將受益匪淺，進而降低價格談判的風險。在貿易政策趨於分化的時代，能夠提供在地化能力和監管協調的製造合作夥伴將帶來實際的價值。此外，投資於數位健康解決方案和患者支援平台的公司可以顯著提高依從性和長期療效，從而為付款人和臨床醫生創造差異化的價值提案。

產業領導者應採取指南，加速取得藥物、增強供應彈性，並最大限度地發揮嗜睡症治療的臨床和商業性潛力

領導者應採取組合式方法，在短期可及性努力與機制創新和證據產生的長期投資之間取得平衡。首先，優先考慮供應鏈多元化和二級供應商資格認證，以降低貿易中斷對企業的影響。其次，在臨床計畫早期納入付款人參與和衛生經濟證據開發，使臨床試驗終點與報銷預期相一致，並支持基於價值的合約談判。第三，投資數位化工具和整合護理模式，以增強診斷、監測依從性並捕捉對患者和付款人重要的功能性結果。

此外，企業應尋求有針對性的合作夥伴關係，將治療專業知識與生產、監管策略和患者支持能力相結合。此類合作關係應以共擔風險、加速市場准入為目標，並設定與臨床和商業性目標掛鉤的明確里程碑。最後，採取積極主動的政策和倡導議程，強調持續獲得基本嗜睡症藥物的醫療需求，並在適當情況下推廣簡化海關程序和關稅減免。

此項分析將一手質性研究與結構化的二次證據結合，以確保獲得全面、立體的觀點。一手研究包括對臨床醫生、付款方和監管專家、製造和供應鏈負責人以及患者權益代表的深入訪談，以收集經驗見解和營運現狀。二次研究涵蓋同行評審的臨床文獻、監管指南文件、臨床試驗註冊中心和公共聲明，以建立關於治療機制、安全性和治療指南的基準事實。

此分析方法將主題定性綜合分析與基於情境的影響評估相結合，以評估跨細分市場和區域的策略影響。研究結果透過多位專家的最後覆核和迭代審查週期進行檢驗，以最大程度地減少偏差。鑑於貿易政策和持續臨床開發的性質可能會迅速改變動態，本分析強調方向性洞察和策略槓桿，而非固定的預測。

將臨床需求、商業策略和營運準備結合起來，為嗜睡症照護的相關人員制定一條連貫的前進道路

發作性睡病既是持續的臨床挑戰，也是治療創新的動態機會。機制理解、診斷途徑的改進以及支付方期望的不斷變化，為能夠帶來顯著功能改善的治療方法創造了肥沃的土壤。然而，要實現這一潛力，需要多方面採取審慎的行動，包括產生與臨床意義終點相符的強力證據、構建能夠預測貿易和關稅相關影響的彈性供應鏈，以及協調製造商、支付方和醫療保健提供者獎勵的商業模式。

總而言之，將科學嚴謹性、營運務實精神和積極的付款人參與相結合的相關人員，將最有可能改善患者治療效果，並實現永續的商業性成功。這需要對研究、製造和上市能力進行協調一致的投資，並建立夥伴關係關係，以彌補能力差距，加速將創新轉化為可近的醫療保健。透過果斷地採取這些優先事項，申辦者和醫療保健提供者能夠實現為發作性睡病患者提供更好、更公平治療的承諾。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • Pitolisant 成為首個組織胺 H3 受體拮抗劑，重塑嗜睡症市場的競爭格局
  • 推出 Solriamfetol，該藥物在減少嗜睡症患者白天過度嗜睡方面表現出色
  • 個人化遠端醫療追蹤的整合可提高發作性睡病治療通訊協定的依從性和療效
  • 不斷發展的數位健康平台，為嗜睡症管理提供即時症狀追蹤和行為矯正
  • 擴展我們的非刺激性化合物產品線，針對Orexin受體調節以外的新型神經傳導物質通路
  • 製藥公司與睡眠研究中心的策略合作加速了嗜睡症治療的發展
  • 患者報告結果測量對於推動嗜睡症治療市場進入策略的重要性日益增加

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 發作性睡病治療市場（依藥物類別）

  • 抗憂鬱症
  • Orexin受體促效劑
  • 羥基丁酸鈉
  • 興奮劑

第9章 發作性睡病治療市場（依疾病類型）

  • 1型嗜睡症
  • 2型嗜睡症

第 10 章。嗜睡症治療市場（依年齡層）

  • 成人
  • 老年人
  • 孩子們

第 11 章。嗜睡症治療市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第12章 嗜睡症治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 嗜睡症治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。各國嗜睡症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AstraZeneca plc
    • Avadel Pharmaceuticals
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Cipla Limited
    • Eli Lilly and Company
    • Glenmark Pharmaceuticals Limited
    • Indivior plc
    • Jazz Pharmaceuticals plc
    • Johnson & Johnson Services, Inc.
    • Lannett Company, Inc.
    • Lupin Limited
    • Merck & Co., Inc.
    • Mylan NV by Viartis
    • NLS Pharmaceutics
    • Novartis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Limited
Product Code: MRR-036C5CF3B447

The Narcolepsy Treatment Market is projected to grow by USD 3.99 billion at a CAGR of 8.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.14 billion
Estimated Year [2025] USD 2.31 billion
Forecast Year [2032] USD 3.99 billion
CAGR (%) 8.06%

A focused introduction that frames narcolepsy as a strategic therapeutic area where clinical need, regulatory progress, and commercial opportunity intersect

Narcolepsy remains a clinically complex neurological disorder characterized by excessive daytime sleepiness, disrupted nocturnal sleep, and, in many patients, cataplexy. This constellation of symptoms drives significant impairment in quality of life and workplace productivity, and it presents distinctive challenges for diagnosis, long-term management, and therapeutic innovation. Over recent years, advances in pharmacology and a deeper understanding of orexin biology have elevated narcolepsy from a largely symptom-managed condition to a field where disease-modifying mechanisms are being actively explored. Consequently, stakeholders across research, clinical practice, payer communities, and patient advocacy groups are recalibrating priorities to better align clinical benefit with access and affordability.

Against this clinical backdrop, market participants face a dual mandate: accelerate the translation of promising scientific approaches into safe, effective therapies while ensuring equitable patient access and sustainable commercial models. The ecosystem is evolving rapidly, with a greater emphasis on real-world evidence generation, integrated care pathways that combine pharmacotherapy with behavioral and technological interventions, and innovative pricing models that reflect long-term outcomes. For decision-makers, this introduction highlights the imperative to balance near-term operational execution with longer-term investments in research, partnerships, and manufacturing resilience to meet both patient needs and stakeholder expectations.

Transformative shifts in the narcolepsy treatment landscape driven by novel mechanisms, patient-centric care, and evolving regulatory expectations

The landscape for narcolepsy treatment is changing in several convergent ways. Mechanistic innovation, particularly efforts to modulate orexin signaling, is shifting clinical conversation from symptomatic control toward more targeted interventions that directly address core pathophysiology. These scientific advances are complemented by improvements in diagnostic pathways, including greater clinician awareness, expanded use of objective sleep testing, and digital tools that support symptom tracking and remote assessment. As a result, the profile of diagnosed patients is broadening, and earlier identification of candidates for advanced therapies is becoming feasible.

Simultaneously, payer policies and regulatory frameworks are adapting to accommodate novel therapeutic modalities and value-based contracting approaches. Health systems increasingly prioritize outcomes-driven reimbursement tied to functional gains rather than solely short-term symptom relief. Patient-centric care models are also gaining traction, with multidisciplinary clinics integrating pharmacologic treatment with behavioral interventions and assistive technologies. Taken together, these shifts create windows of opportunity for sponsors and providers to differentiate through evidence generation, patient support programs, and partnerships that streamline diagnostic-to-treatment pathways while managing real-world safety and adherence considerations.

An evidence-based appraisal of how the United States tariff environment in 2025 will influence supply chains, manufacturing strategies, and patient access for narcolepsy therapies

Trade policy adjustments and tariff realignments in 2025 are creating renewed scrutiny of global pharmaceutical supply chains. For narcolepsy therapies, the implications are multidimensional: active pharmaceutical ingredients and key excipients that cross borders face heightened cost volatility and potential customs delays, which in turn can affect production scheduling for both branded and generic formulations. Manufacturers are responding by evaluating nearshoring options, diversifying supplier bases, and accelerating qualification of alternative sources to mitigate disruption. These operational responses are essential to preserving supply continuity and avoiding inventory shortfalls that can harm patient care.

Beyond operational considerations, tariff-related uncertainty is influencing strategic planning across the value chain. Payers and providers are preparing for a potential pass-through of higher procurement costs and are exploring procurement strategies that emphasize long-term contracts, manufacturer rebates, and manufacturer-supported patient assistance programs. Regulators and customs authorities are also under pressure to streamline import processes for essential medicines, and stakeholders are increasingly advocating for tariff exemptions or rapid clearance pathways for critical therapeutic categories. In sum, the 2025 tariff environment is prompting a pragmatic shift toward supply chain resilience, contractual flexibility, and closer collaboration between manufacturers, distributors, and health systems to safeguard patient access.

Strategic segmentation insights that illuminate therapeutic priorities, patient population nuances, and distribution dynamics relevant to decision-makers in the narcolepsy space

A nuanced segmentation framework clarifies where clinical demand, development focus, and commercial channels intersect. Based on Drug Class, market study areas include Antidepressants, Orexin Receptor Agonists, Sodium Oxybate, and Stimulants, each of which carries distinct efficacy-safety profiles and clinical positioning that influence prescribing patterns and follow-up care. Based on Disorder Type, the differential presentation and management of Narcolepsy Type 1 and Narcolepsy Type 2 inform diagnostic algorithms, eligibility for specific therapeutics, and trial design considerations for novel agents. Based on Age Group, distinctions among Adults, Geriatrics, and Pediatrics require tailored dosing strategies, safety monitoring protocols, and supportive services that reflect developmental and comorbidity differences. Based on Distribution Channel, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies present varying operational, regulatory, and patient-experience implications, from adherence support to reimbursement workflows.

Integrating these segmentation lenses yields several actionable implications. Therapeutic development programs should align mechanism-of-action hypotheses with the dominant clinical phenotype segments to optimize trial enrollment and meaningful endpoints. Commercial strategies must differentiate channel-specific value propositions: hospital pharmacy channels often center on complex dispensing and inpatient continuity, online pharmacy channels emphasize access and convenience, while retail pharmacies support point-of-care counseling and ongoing adherence. Patient support programs should be calibrated by age group and disorder subtype to address real-world adherence barriers and comorbidity management. Finally, segmentation-driven evidence generation-such as subgroup analyses and channel-specific health economic assessments-will strengthen payer dialogues and clinical uptake across diverse care settings.

Key regional perspectives that highlight how geographic differences in regulation, healthcare infrastructure, and payer models shape access and commercialization of narcolepsy treatments

Regional dynamics exert a significant influence on how narcolepsy treatments are developed, approved, and reimbursed. In the Americas, clinical practice patterns and payer structures create an environment where innovation can be rapidly adopted when supported by robust evidence of functional improvement, and manufacturers often prioritize large-scale registries and outcomes studies to inform reimbursement conversations. In Europe, Middle East & Africa, heterogeneous regulatory pathways and varying levels of healthcare infrastructure require market strategies that emphasize flexible pricing models, local partnerships for distribution, and capacity-building initiatives to improve diagnostic reach. In the Asia-Pacific region, rapid urbanization, growing specialty care networks, and differing regulatory expectations drive a mix of centralized national procurement and regional market access approaches that favor scalable manufacturing and culturally adapted patient support programs.

Across these regions, stakeholders must reconcile global development plans with localized access strategies. Harmonizing clinical trial endpoints with region-specific regulatory requirements and investing in real-world data collection across geographies will accelerate reimbursement and uptake. Moreover, regional manufacturing footprints and strategic alliances with local distributors can mitigate customs and tariff-related risks while improving lead times for critical therapies. Ultimately, a nuanced regional approach that balances global evidence generation with local market shaping will be essential to maximize therapeutic impact and facilitate sustainable patient access.

Key company-level insights that reveal strategic postures, capability gaps, and partnership opportunities across innovators, generics manufacturers, and service providers in the narcolepsy ecosystem

Companies competing or collaborating in narcolepsy are differentiating through distinct strategic choices. Innovator firms with proprietary agents often emphasize integrated evidence programs that combine controlled trials with real-world safety and health outcomes research to justify premium positioning. Specialty biotechs focus on novel mechanisms and niche indications, seeking partnerships or licensing deals to accelerate development and access. Generic and established pharmaceutical manufacturers concentrate on scale, cost-efficient manufacturing, and dependable distribution networks to meet demand for established treatments. Service providers and contract manufacturers are positioning themselves as resilience enablers, offering supply-chain redundancy, rapid regulatory filing support, and quality-assurance services that reduce time-to-market risk.

Across these company types, several capability gaps present partnership opportunities. Many developers would benefit from deeper payer-engagement expertise and health economics modeling earlier in development to de-risk pricing negotiations. Manufacturing partners that can provide localized capacity and regulatory alignment offer tangible value in an era of trade policy variability. Additionally, firms investing in digital health solutions and patient-support platforms can materially improve adherence and long-term outcomes, creating differentiated value propositions for payers and clinicians. Strategic alliances that combine therapeutic innovation with scale manufacturing, market access acumen, and digital adherence tools will likely define the next wave of successful commercialization efforts.

Actionable recommendations for industry leaders to accelerate access, strengthen supply resilience, and maximize the clinical and commercial potential of narcolepsy therapies

Industry leaders should adopt a portfolio approach that balances near-term access initiatives with longer-term investments in mechanistic innovation and evidence generation. First, prioritize supply-chain diversification and qualification of secondary suppliers for critical inputs to reduce vulnerability to trade disruptions, while also exploring regional manufacturing partnerships to shorten delivery timelines. Second, embed payer engagement and health economic evidence development early in clinical programs to align trial endpoints with reimbursement expectations and to support value-based contracting discussions. Third, invest in digital tools and integrated care models that enhance diagnosis, monitor adherence, and capture functional outcomes that matter to patients and payers.

Additionally, companies should pursue targeted collaborations that pair therapeutic expertise with capabilities in manufacturing, regulatory strategy, and patient support. These alliances should be structured to share risk and accelerate market entry, with clear milestones tied to clinical and commercial objectives. Finally, adopt a proactive policy and advocacy agenda that emphasizes the medical necessity of uninterrupted access to essential narcolepsy therapies, promoting streamlined customs procedures and tariff exemptions where appropriate. Taken together, these recommendations provide a pragmatic roadmap to improve patient outcomes while safeguarding

Transparent research methodology describing sources, analytic approaches, and validation procedures used to ensure the reliability and relevance of narcolepsy market insights

This analysis synthesizes primary qualitative research and structured secondary evidence to ensure a comprehensive, triangulated perspective. Primary research included in-depth interviews with clinicians, payers, regulatory specialists, manufacturing and supply-chain leaders, and patient advocacy representatives to capture experiential insights and operational realities. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and public policy statements to establish a factual baseline for therapeutic mechanisms, safety profiles, and treatment guidelines. Data from treatment registries and health-system protocols were reviewed where available to contextualize real-world practice patterns.

Analytic methods combined thematic qualitative synthesis with scenario-based impact assessment to evaluate strategic implications across segmentation and regions. Findings were validated through cross-checks with multiple expert respondents and iterative review cycles to minimize bias. Limitations are acknowledged: the evolving nature of trade policy and ongoing clinical development can alter dynamics rapidly, and therefore the analysis emphasizes directional insights and strategic levers rather than fixed projections. Where applicable, potential data gaps are highlighted, and recommended follow-up research steps are provided to support deeper, program-specific decision-making.

Concluding synthesis that connects clinical needs, commercial strategy, and operational readiness to chart a coherent path forward for stakeholders in narcolepsy care

Narcolepsy represents both a persistent clinical challenge and a dynamic opportunity for therapeutic innovation. The convergence of mechanistic science, improved diagnostic pathways, and evolving payer expectations creates fertile ground for therapies that deliver meaningful functional improvement. However, realizing that potential requires deliberate action across multiple domains: robust evidence generation tailored to clinically meaningful endpoints, resilient supply chains that anticipate trade and tariff-related disruptions, and commercial models that align incentives across manufacturers, payers, and providers. Patient-centered approaches, including digital monitoring and targeted support services, will be essential to translate pharmacologic advances into durable real-world benefits.

In conclusion, stakeholders who integrate scientific rigor with operational pragmatism and proactive payer engagement will be best positioned to improve patient outcomes while achieving sustainable commercial success. The path forward involves coordinated investment in research, manufacturing, and market access capabilities, alongside partnerships that bridge capability gaps and accelerate the translation of innovation into accessible care. By acting decisively on these priorities, sponsors and providers can deliver on the promise of better, more equitable care for people living with narcolepsy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advent of pitolisant as first histamine H3 receptor antagonist reshaping competitive dynamics in the narcolepsy market
  • 5.2. Emergence of solriamfetol demonstrating superior efficacy in reducing excessive daytime sleepiness among narcolepsy patients
  • 5.3. Integration of personalized telemedicine follow-up improving adherence and outcomes in narcolepsy treatment protocols
  • 5.4. Growth of digital health platforms offering real-time symptom tracking and behavior modification for narcolepsy management
  • 5.5. Expansion of non-stimulant pipeline compounds targeting novel neurotransmitter pathways beyond orexin receptor modulation
  • 5.6. Strategic collaborations between pharmaceutical firms and sleep research centers accelerating narcolepsy drug development
  • 5.7. Increasing emphasis on patient-reported outcome measures driving market access strategies for narcolepsy therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Narcolepsy Treatment Market, by Drug Class

  • 8.1. Antidepressants
  • 8.2. Orexin Receptor Agonists
  • 8.3. Sodium Oxybate
  • 8.4. Stimulants

9. Narcolepsy Treatment Market, by Disorder Type

  • 9.1. Narcolepsy Type 1
  • 9.2. Narcolepsy Type 2

10. Narcolepsy Treatment Market, by Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Narcolepsy Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Narcolepsy Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Narcolepsy Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Narcolepsy Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AstraZeneca plc
    • 15.3.2. Avadel Pharmaceuticals
    • 15.3.3. Bayer AG
    • 15.3.4. Boehringer Ingelheim GmbH
    • 15.3.5. Cipla Limited
    • 15.3.6. Eli Lilly and Company
    • 15.3.7. Glenmark Pharmaceuticals Limited
    • 15.3.8. Indivior plc
    • 15.3.9. Jazz Pharmaceuticals plc
    • 15.3.10. Johnson & Johnson Services, Inc.
    • 15.3.11. Lannett Company, Inc.
    • 15.3.12. Lupin Limited
    • 15.3.13. Merck & Co., Inc.
    • 15.3.14. Mylan N.V. by Viartis
    • 15.3.15. NLS Pharmaceutics
    • 15.3.16. Novartis AG
    • 15.3.17. Pfizer Inc.
    • 15.3.18. Sun Pharmaceutical Industries Ltd.
    • 15.3.19. Takeda Pharmaceutical Company Limited
    • 15.3.20. Teva Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NARCOLEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NARCOLEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NARCOLEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY OREXIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY SODIUM OXYBATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY STIMULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY NARCOLEPSY TYPE 2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 89. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 91. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 100. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 110. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 116. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 127. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 140. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 150. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 151. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 304. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 305. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 320. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 321. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 332. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 333. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 334. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 336. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. AUSTRALIA NARCOLEPSY TREATM